Neximmune Inc

NASDAQ NEXI

Data sourced from

and

Daily

Download Data

Neximmune Inc Price to Earnings Ratio (P/E) on June 03, 2024: -0.56

Neximmune Inc Price to Earnings Ratio (P/E) is -0.56 on June 03, 2024, a -257.21% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.

Neximmune Inc 52-week high Price to Earnings Ratio (P/E) is -0.02 on April 16, 2024, which is 95.61% above the current Price to Earnings Ratio (P/E).
Neximmune Inc 52-week low Price to Earnings Ratio (P/E) is -4.24 on October 17, 2023, which is -654.56% below the current Price to Earnings Ratio (P/E).
Neximmune Inc average Price to Earnings Ratio (P/E) for the last 52 weeks is -0.47.

NASDAQ: NEXI

Neximmune Inc

CEO	Ms. Kristi Jones R.Ph.
IPO Date	Feb. 12, 2021
Location	United States
Headquarters	9119 Gaither Road, Gaithersburg, MD, United States, 20877
Employees	6
Sector	Healthcare
Industry	Biotechnology

Description

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Key trends